---
layout: default
title: Activated Charcoal Ambergris Ammonium Chloride Arn
parent: 僅模型預測 (L5)
nav_order: 169
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Ambergris Ammonium Chloride Arn
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Herbal/Homeopathic Complex: Repurposing Evaluation Not Applicable

## One-Sentence Summary

This submission contains a complex mixture of eight components — including Activated Charcoal, Atropa Belladonna, Arnica Montana, and Claviceps Purpurea — whose profile resembles a homeopathic combination product.
The TxGNN model returned **no predicted indications** for this compound, and the drug holds **no US market authorizations**.
Without a defined single active ingredient, DrugBank mapping, or TxGNN output, a standard repurposing evaluation cannot proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Unknown — no approved indication on record |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; in this case, no output at all |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This submission is not a single molecular entity but a mixture of eight pharmacologically distinct substances:

| Component | Known Pharmacological Class |
|---|---|
| Activated Charcoal | Non-specific adsorbent |
| Ambergris | Historical fragrance/fixative; no defined pharmacology |
| Ammonium Chloride | Expectorant / urinary acidifier |
| Arnica Montana | Topical anti-inflammatory (homeopathic) |
| Atropa Belladonna | Anticholinergic (source of atropine/scopolamine) |
| Baptisia Tinctoria Root | Immune stimulant (homeopathic) |
| Claviceps Purpurea Sclerotium | Ergot alkaloid source (homeopathic dilution) |
| Filipendula Ulmaria Root | Anti-inflammatory (contains natural salicylates) |

The TxGNN knowledge graph operates on single-drug entities matched to DrugBank IDs. This combination product could not be assigned a DrugBank ID, which means the model had no node to traverse — producing an empty prediction set rather than a meaningful score.

The combination profile is consistent with a **classical homeopathic compound formula**, where each ingredient is present at high dilution and the claimed therapeutic mechanism differs fundamentally from conventional pharmacology. This category of product falls outside the scope of TxGNN-based repurposing analysis.

---

## US Market Information

No US market authorizations found. This product has zero NDAs on record.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note for reviewers**: Atropa Belladonna contains atropine and scopolamine, which carry anticholinergic risks even at low doses. Claviceps Purpurea (ergot) is a source of vasoconstrictive alkaloids. If any future formulation development moves beyond homeopathic dilutions, a dedicated safety assessment for these two components is strongly recommended.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model produced no output because this multi-component mixture cannot be mapped to a single DrugBank entity, which is a prerequisite for knowledge-graph traversal. There is no original indication, no US market presence, and no evidence base to evaluate.

**To proceed, the following is needed:**

- **Reformulate the query**: If the intent is to evaluate a specific component (e.g., Atropa Belladonna / atropine, or Filipendula Ulmaria), resubmit as a single-ingredient query with the appropriate DrugBank ID.
- **Clarify product identity**: Confirm whether this is a licensed homeopathic product, an investigational botanical combination, or a data entry artifact.
- **Obtain regulatory classification**: Determine whether the product would be regulated as a drug, dietary supplement, or homeopathic remedy under US FDA rules — each pathway has different evidence requirements.
- **Manual literature review**: If the combination is of genuine research interest, a manual PubMed search by individual component is feasible, but TxGNN-driven repurposing is not applicable in the current form.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

